ClinicalTrials.gg
CompletedNCT05830968Updated Nov 17, 2026

Safety and Efficacy of Radio Frequency for the Treatment of Mild to Severe Inflammatory Acne

An interventional study of Morpheus8 Applicator Radiofrequency device in Inflammatory Acne Vulgaris, sponsored by InMode MD Ltd.. Completed at 4 sites in United States. Open to participants aged 16 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by InMode MD Ltd. (part of InMode Ltd.) · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was May 2025, 1 year 6 months ago, and no results have been posted to the registry.
Updated Nov 17, 2026Now CompletedEnrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
46
Allocation
Not applicable
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 374 studies in Acne Vulgaris with a site in United States — 20 open to participants now, 29 under way, 2 of them phase 3. Acne Vulgaris · United States.

Enrollment
226th of 354
46 · median 78
Started
2023
with 18 others
No phase
78 of 374
9 open now
Registered
324th of 374
by date

Among the 374 studies in Acne Vulgaris with a site in United States, this one is the 226th largest by enrollment of the 354 interventional ones that give a count, is one of 19 that started in 2023, is one of 78 with no phase, and was the 324th registered.

Acne Vulgaris

795 studies on the registry are indexed under Acne Vulgaris; 96 are open to participants now.

Browse Acne Vulgaris studies →

Open to participants now

20 of the 374 studies in Acne Vulgaris with a site in United States are open now. Recruiting first, the newest first:

15 more — sign in →

All 20 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 48 Acne Vulgaris studies recruiting now, 17 (35%) set no upper age limit and 30 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.

This study: 16 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 374 studies in Acne Vulgaris with a site in United States, or all of them as a file.
02

Study summary

The aim of this trial is to evaluate the safety and efficacy of the InMode RF Pro System with the Morpheus8 face tip (24 pins) applicator for the treatment of mild, moderate and severe, facial acne vulgaris

Read the detailed description

The aim of this trial is to evaluate the safety and efficacy of the InMode RF Pro System with the Morpheus8 face tip (24 pins) applicator for the treatment of mild, moderate and severe, facial acne vulgaris. Prospective, multicenter clinical study

03

Conditions studied

  • Inflammatory Acne Vulgaris

Browse trials for

04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

  • Subject is >16 years of age
  • General good health confirmed by medical history and examination of the treated area.
  • Subjects with mild to severe Acne Vulgaris, defined as a baseline IGA (Investigator's Global Assessment) score of 2, 3 or 4 and 10-100 inflammatory lesions (papules or pustules).
  • The patients should be willing to comply with the study procedure and schedule, including the follow up visits, and will refrain from using any other acne treatment methods during the entire study period.
  • Willing to avoid sun/UV exposure for duration of the study unless using sunscreen.
  • Willing to refrain from starting or changing hormonal for duration of study.
  • Subject understands and is willing to sign the to participate in the study. Parental (or other) guardians must provide consent for minors under the age of 18.

Exclusion Criteria:- Pacemaker or internal defibrillator, or any other active electrical implant anywhere in the body.

  • Patients who are under pharmacological anti-acne therapy (isotretinoin or antibiotics) for the last 6 months.
  • Use of botulinum toxin within prior 1 month.
  • Permanent implant in the treated area such as metal plates and screws, silicone implants or an injected chemical substance
  • Current or history of cancer, or premalignant condition in the treatment area.
  • Severe concurrent conditions, such as cardiac disorders, epilepsy, uncontrolled hypertension, and liver or kidney diseases.
  • Subject who are pregnant or nursing.
  • Started or changed hormonal contraceptive within prior month of study.
  • Subject is unwilling or unlikely to refrain from high UV exposure to face.
  • Impaired immune system due to diseases such as AIDS and , or use of immunosuppressive medications.
  • Patients with history of diseases stimulated by heat, such as recurrent Herpes Simplex in the treatment area
  • Poorly controlled endocrine disorders, such as diabetes or thyroid dysfunction.
  • Any active condition in the treatment area, such as sores, psoriasis, eczema, and rash.
  • History of skin disorders, keloids, abnormal wound healing, as well as very dry and fragile skin.
  • History of bleeding coagulopathies or use of anticoagulants in the last 10 days.
  • Any surgery in treated area within 3 months prior to treatment.
  • Subject received other treatments such as light, CO2 laser or RF in the treatment area within 6 months of study start date.
  • Simultaneous participation in another investigator drug or device study or completion of the follow-up phase for the primary endpoint of any previous study less than 30 days prior to the first evaluation in this study.
  • Subject that has any condition that, at the investigator's discretion, renders the subject unsuitable for participation in this clinical research study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
46 participants (actual)

Study arms

  • Experimental
    Device treatment

    Treatment area will include affected areas over the entire face (presence of comedones, pustules, papules, nodules and cysts

    Device: Morpheus8 Applicator Radiofrequency device

Interventions

  • DeviceMorpheus8 Applicator Radiofrequency device

    Eligible subjects will receive 2 treatments with the Morpheus8 according to the study protocol. All participants will return for 2 follow up visits: 4 weeks (1M FU) and 12 weeks (3M FU) after the 2nd treatment. Total expected study duration is \~6 months, depending on subject recruitment rate.

06

What researchers measure

Primary outcomes

  1. Percent of responder

    Percent of responders, where responders are defined as subjects with at least a 50% reduction in number of inflammatory acne lesions from baseline to 12 weeks after the last treatment, as assessed by 3 independent reviewers using clinical photographs. Success Criteria: Success will be achieved if at least 50% of enrolled subjects are responders.

    Time frame: Month 3

Secondary outcomes

  1. Absolute change in number of inflammatory acne lesions

    Absolute change in number of inflammatory acne lesions from baseline to 12 weeks after the last treatment, as assessed by 3 independent reviewers using clinical photographs

    Time frame: Month 3

  2. Percentage of subjects with a ≥2 point score improvement on the Investigators Global Assessment (IGA) scale

    Percentage of subjects with a ≥2 point score improvement on the Investigators Global Assessment (IGA) scale at 12 weeks after the last treatment compared to baseline as assessed by three independent reviewers using clinical photographs.

    Time frame: Month 3

  3. Absolute change in non-inflammatory acne lesions

    Absolute change In non-inflammatory acne lesions from baseline to 12 weeks after the last treatment, as assessed by 3 independent reviewers from clinical photographs

    Time frame: Month 3

  4. The rate of patient satisfaction with treatment,

    The rate of patient satisfaction with treatment, using a 5-point Likert scale at 12 weeks after the last treatment

    Time frame: Month 3

  5. percent change in non-inflammatory acne lesions

    percent change in number of inflammatory acne lesions from baseline to 12 weeks after the last treatment, as assessed by 3 independent reviewers using clinical photographs

    Time frame: Month 3

  6. Percent change in non-inflammatory acne lesions

    Percent change in non-inflammatory acne lesions from baseline to 12 weeks after the last treatment, as assessed by 3 independent reviewers from clinical photographs

    Time frame: Month 3

07

Study locations

4 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2023 to primary completion in May 2025, 24 months.

Of 63 industry-sponsored interventional studies with no phase under Acne Vulgaris, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 19. This study's 24 months is above that.

Counting every sponsor, half of 122 studies reached it within 9 months; a quarter within 4 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 13, 2023
First posted
Apr 26, 2023
StartActual
May 1, 2023
Primary completionActual
May 1, 2025
CompletionActual
May 1, 2026
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 17, 2026
Enrollment
42 (estimated)→46 (actual)
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Recruiting→Completed
    Enrollment 42 (estimated)→46 (actual)
    + 4 other changes: verification date, date precision, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05830968
Lead sponsor
InMode MD Ltd.
Responsible party
Sponsor
First posted
Apr 26, 2023
Start date
May 1, 2023
Primary completion
May 1, 2025
Completion
May 1, 2026
Last update
Nov 17, 2026

Study contacts

Anna M Chapas, MD
principal investigator
Jole L Cohen, MD
principal investigator · Unafilliated

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion